Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
Authors
Keywords
-
Journal
MOLECULES
Volume 25, Issue 17, Pages 3900
Publisher
MDPI AG
Online
2020-08-27
DOI
10.3390/molecules25173900
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- (2019) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Turning the corner on therapeutic cancer vaccines
- (2019) Robert E. Hollingsworth et al. npj Vaccines
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
- (2019) Martin Reck et al. Lancet Respiratory Medicine
- First-line treatment of women with advanced ovarian cancer: focus on bevacizumab
- (2019) Claudia Marchetti et al. OncoTargets and Therapy
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues
- (2019) Hongqing Zhuang et al. Molecular Cancer
- The use of bevacizumab in pediatric retinal and choroidal disease: A review
- (2019) Peter J Belin et al. EUROPEAN JOURNAL OF OPHTHALMOLOGY
- The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer
- (2019) Kirstin Perdrizet et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Prospective randomised clinical trial of intravitreal bevacizumab versus triamcinolone in eyes with diabetic macular oedema undergoing cataract surgery: 6-month results
- (2019) Rathika Kandasamy et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
- (2019) John D. Martin et al. Annual Review of Physiology
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- The Immunoscore: Colon Cancer and Beyond
- (2019) Helen K Angell et al. CLINICAL CANCER RESEARCH
- Dual PD ‐1 and VEGFR ‐2 blockade promotes vascular normalization and enhances anti‐tumor immune responses in HCC
- (2019) Kohei Shigeta et al. HEPATOLOGY
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- Myeloid-derived suppressor cell-dependent inhibition of B cell responses in non-small cell lung cancer
- (2019) Rui Li et al. Translational Lung Cancer Research
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
- (2018) Franck Pagès et al. LANCET
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
- (2018) Michael B Atkins et al. LANCET ONCOLOGY
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- Hypoxia Pathway Proteins As Central Mediators of Metabolism in the Tumor Cells and Their Microenvironment
- (2018) Sundary Sormendi et al. Frontiers in Immunology
- Role of hypoxia-induced exosomes in tumor biology
- (2018) Chuchu Shao et al. Molecular Cancer
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
- (2018) Priyamvada Jayaprakash et al. JOURNAL OF CLINICAL INVESTIGATION
- TIM-3, a promising target for cancer immunotherapy
- (2018) Yayi He et al. OncoTargets and Therapy
- Oncolytic virus immunotherapy: future prospects for oncology
- (2018) Junaid Raja et al. Journal for ImmunoTherapy of Cancer
- Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
- (2018) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
- (2018) Neda Yaghoubi et al. BIOMEDICINE & PHARMACOTHERAPY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?
- (2017) Yanqing Huang et al. Science China-Life Sciences
- Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
- (2016) J. M. Kim et al. ANNALS OF ONCOLOGY
- CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation
- (2016) Vinit Kumar et al. IMMUNITY
- Driving CAR T-cells forward
- (2016) Hollie J. Jackson et al. Nature Reviews Clinical Oncology
- Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
- (2016) Caroline Wigerup et al. PHARMACOLOGY & THERAPEUTICS
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
- (2016) Vinit Kumar et al. TRENDS IN IMMUNOLOGY
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
- (2016) Nicole E. Scharping et al. Cancer Immunology Research
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Immunological mechanisms of the antitumor effects of supplemental oxygenation
- (2015) Stephen M. Hatfield et al. Science Translational Medicine
- Adaptive Immune Resistance: How Cancer Protects from Immune Attack
- (2015) A. Ribas Cancer Discovery
- HIF-1α pathway: role, regulation and intervention for cancer therapy
- (2015) Georgina N. Masoud et al. Acta Pharmaceutica Sinica B
- Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
- (2015) Patrick A. Ott et al. Frontiers in Oncology
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
- (2013) M. Sznol et al. CLINICAL CANCER RESEARCH
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
- (2013) Jonathan Welti et al. JOURNAL OF CLINICAL INVESTIGATION
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
- (2013) Taku Okazaki et al. NATURE IMMUNOLOGY
- Neuropilin-1Stimulates Tumor Growth by Increasing Fibronectin Fibril Assembly in the Tumor Microenvironment
- (2012) Usman Yaqoob et al. CANCER RESEARCH
- Targeting the Tumor Microenvironment for Cancer Therapy
- (2012) N. E. Sounni et al. CLINICAL CHEMISTRY
- The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells
- (2012) Dennis Lindau et al. IMMUNOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth
- (2012) Taku Fujimura et al. OncoImmunology
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Epigenetic cancer therapy: rationales, targets and drugs
- (2011) M Rius et al. ONCOGENE
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Activated STAT3 is a mediator and biomarker of VEGF endothelial activation
- (2010) Shao-Hua Chen et al. CANCER BIOLOGY & THERAPY
- Vascular Endothelial Growth Factor: Much More than an Angiogenesis Factor
- (2010) Donald R. Senger MOLECULAR BIOLOGY OF THE CELL
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Co-evolution of tumor cells and their microenvironment
- (2008) Kornelia Polyak et al. TRENDS IN GENETICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More